Sigachi Industries Q3 FY26 Earnings Call Transcript Released
Sigachi Industries released its Q3 FY26 earnings call transcript. The company reported Q3 revenue of ₹117.2 crore and EBITDA of ₹5.7 crore. Capacity expansions at Dahej are on track for Q3 FY27. The company anticipates a return to normalcy and double-digit EBITDA from FY27/FY28. Insurance claims for the Hyderabad incident are estimated at ₹70 crore.
The announcement provides crucial operational and financial updates, including capacity expansion plans and recovery from past incidents. This information is material for investors in understanding the company's current status and future outlook, influencing investment decisions.
The announcement is a transcript of an earnings call, which is a routine disclosure. While it provides updates on operations and expansions, it also details a net loss and explains reasons for lower EBITDA due to past incidents, balancing positive and negative financial aspects.
Sigachi Industries Limited has released the transcript of its Q3 FY2025-26 earnings conference call, which was held on February 14, 2026. The call featured insights from Managing Director and CEO Mr. Amit Raj Sinha, CFO Mr. O.S. Reddy, and Company Secretary Mr. Vivek Kumar.
Mr. Sinha highlighted the company's focus on rebuilding with stronger systems, accountability, and resilience, emphasizing ongoing work in EHS systems and operational discipline. He noted that plants are running at planned capacity with stable supply chains and strong customer demand. The current cellulose-based excipient capacity stands at approximately 18,000 metric tons per annum, with exports constituting 62% of production. Capacity expansion plans are progressing, with the 12,000 metric tons per annum MCC Dahej expansion and an 1,800 tons CCS disintegrant facility at Dahej SEZ targeted for commissioning in Q3 FY27. The company anticipates a return to normalcy and growth from FY27 onwards, with an expectation of double-digit EBITDA from FY28.
CFO Mr. O.S. Reddy reported total operating income of ₹117.2 crores for Q3 FY26, with EBITDA at ₹5.7 crores (4.6% margin) and a net loss of ₹0.02 crores. The lower EBITDA was attributed to the impact of the Hyderabad unit incident, including overhead allocation and increased transportation costs. The company expects performance to improve from Q4 FY26 and normalize in FY27.
Discussions also covered insurance claims related to the Hyderabad incident, estimated at ₹70 crores in total, with an ad-hoc payment of ₹20-25 crores expected by March 31, 2026. The company is not currently considering reopening the Hyderabad facility, focusing instead on the Dahej SEZ expansion. Regarding the API segment, Metformin has received CEP approval, and other CEPs are in process. The company is confident in securing commercial partners for its APIs, with a target of ₹250 crores revenue from Cystic Fibrosis API after 12 months of commercialization.
What to do with a filing like this
Sigachi Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sigachi Industries Limited. Read the original for the full detail.